A new study shows that epitranscriptomics, or chemical regulation of gene expression at the RNA level, determines whether ...
These are heady days for PharmaEssentia, a biotech that got its start 23 years ago in Taiwan, went public 10 years later and ...
Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic ...
FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this ...
Discover essential information about Chronic Lymphocytic Leukemia (CLL), its diagnosis, symptoms, and treatment options in ...
Karyopharm Therapeutics Inc. ( KPTI) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking Accelerated Approval for XPOVIO in combination with Ruxolitinib ...
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at ...
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) today announced the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) ...
The EXODUS H-600 offers an automated, scalable approach to exosome isolation, which should reduce hands-on processing and ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
9hon MSN
Cancer's malignant remote control: How tumors reprogram liver fat metabolism to disarm immune cells
In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the ...
NDA Submitted under the Accelerated Approval Pathway; Priority Review Requested - NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results